Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

2:29am IST
Change (% chg)

$0.13 (+12.75%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer... (more)
No analyst recommendations are available for .


Beta: 1.50
Market Cap(Mil.): kr478.06
Shares Outstanding(Mil.): 176.41
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Oasmia CFO resigns

* Oasmia Pharmaceutical Ab Announces Resignation Of Its Chief Financial Officer

04 Oct 2017

BRIEF-Nexttobe extends loan to Oasmia Pharmaceutical

* Nexttobe extends loan to Oasmia Pharmaceutical Further company coverage: (Reporting by Stockholm Newsroom)

02 Oct 2017

BRIEF-Oasmia Q1 operating loss lower

* Says Q1 operating loss was TSEK 28,421 compared to TSEK 32,343 in Q1 previous year

01 Sep 2017

BRIEF-Oasmia Pharmaceutical says receives market approval for anti-cancer drug in Russia

* Receives Market Approval For Its Anti-cancer Drug Doxophos® in Russia Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

08 Aug 2017

BRIEF-Oasmia Pharmaceutical says through rights issue, its share capital up by 5 mln SEK to 17.6 mln SEK

* Says through rights issue, Oasmia's share capital increases by sek 5 million to sek 17.6 million

08 Jul 2017

BRIEF-Oasmia enters into marketing, distribution agreement concerning Russia, other markets

* Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

14 Jun 2017

BRIEF-Oasmia says enters into new marketing and distribution agreement for Russia and CIS

* Oasmia pharmaceutical enters into new exclusive marketing and distribution agreement concerning russia and other cis markets Source text for Eikon: Further company coverage: (Stockholm Newsroom)

14 Jun 2017

BRIEF-Oasmia to carry out preferential rights issue of around 164 mln SEK

* The Board Of Directors Resolves Upon A Rights Issue Of Approximately 163.9 MSEK

12 Jun 2017

BRIEF-Oasmia Pharmaceutical agreed with holders of convertibles to replace loans with new debt

* Agreed with holders of convertibles in co's convertible loan programme 2016:2 to replace convertible loans with new debt Source text for Eikon: Further company coverage:

09 Jun 2017

BRIEF-Oasmia Q4 operating loss widens

* Q4 consolidated net sales amounted to 44,000 SEK compared to 59,000 in q4 previous year

08 Jun 2017

Earnings vs. Estimates